Abstract

Background In systemic amyloidosis, disease is caused by extracellular accumulation of amyloid fibrils which, unlike other interstitial debris, are not cleared and which disrupt tissue structure and function. Direct removal of amyloid deposits is required to preserve and possibly restore tissue and organ function. We are targeting serum amyloid P component (SAP) for this purpose. SAP normal plasma protein is a normal plasma protein which binds to all amyloid fibrils and is thus always present in all human amyloid deposits. Administration of hexanoyl bis (D–proline) (CPHPC) swiftly depletes circulating SAP but leaves some SAP in amyloid deposits as an amyloidspecific antigen target. In human SAP transgenic mice with systemic AA amyloidosis, CPHPC treatment, to deplete human SAP from the plasma, followed by a single dose of anti-human SAP antibodies produced swift, almost complete, clearance of visceral amyloid (Bodin et al. Nature, 2010;468:93-7). In a mouse SAA transgenic systemic amyloidosis model, which uniquely includes cardiac amyloid, a second dose of anti–SAP antibody, after the first dose had eliminated massive liver and spleen deposits, significantly removed amyloid from the heart (Simons et al. Proc Natl Acad Sci USA. 2013;110:1611520). Amyloid clearance by anti-SAP antibody required classical complement pathway activation and macrophages. Amyloid destruction was mediated by multinucleated giant cells (MGCs), formed by macrophage fusion. MGCs have abundant surface membrane ruffles, enabling the engulfment of very large complement opsonised amyloid targets which were then swiftly destroyed within phagolysosomes. Amyloid clearance was maximal by 14 days. No ill effects were detected. After licensing this new treatment in February 2009, GlaxoSmithKline (GSK) fully humanised our optimal mouse monoclonal anti-SAP antibody and prepared for the first in human clinical study that started in June 2013. We have lately reported that a single dose of humanized monoclonal anti-SAP antibody, following depletion of circulating SAP by CPHPC, substantially reduced the amyloid load, especially from the liver, in patients with systemic AL, AA and AApoAI amyloidosis, (Richards et al, New Engl J Med, July 15 2015; DOI: 10.1056/NEJMoa1504942).

Highlights

  • In systemic amyloidosis, disease is caused by extracellular accumulation of amyloid fibrils which, unlike other interstitial debris, are not cleared and which disrupt tissue structure and function

  • serum amyloid P component (SAP) normal plasma protein is a normal plasma protein which binds to all amyloid fibrils and is always present in all human amyloid deposits

  • Efficacy in amyloid removal requires a sufficient dose of antibody and is associated with a transient early acute phase response of CRP and SAA, transient early mild neutrophilia and notable depletion of plasma C3 and a less marked fall in C4 and CH50 (Richards et al, New Engl J Med, July 15 2015)

Read more

Summary

Background

Disease is caused by extracellular accumulation of amyloid fibrils which, unlike other interstitial debris, are not cleared and which disrupt tissue structure and function. Direct removal of amyloid deposits is required to preserve and possibly restore tissue and organ function. Administration of hexanoyl bis (D–proline) (CPHPC) swiftly depletes circulating SAP but leaves some SAP in amyloid deposits as an amyloidspecific antigen target. In human SAP transgenic mice with systemic AA amyloidosis, CPHPC treatment, to deplete human SAP from the plasma, followed by a single dose of anti-human SAP antibodies produced swift, almost complete, clearance of visceral amyloid (Bodin et al Nature, 2010;468:93-7). In a mouse SAA transgenic systemic amyloidosis model, which uniquely includes cardiac amyloid, a second dose of anti–SAP antibody, after the first dose had eliminated massive liver and spleen deposits, significantly removed amyloid from the heart Amyloid clearance by anti-SAP antibody required classical complement pathway activation and macrophages. After licensing this new treatment in February 2009, GlaxoSmithKline (GSK) fully humanised our optimal mouse monoclonal

Methods
Results
Conclusions
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call